Craft

Neovasc

Stock Price

$40.2

2023-04-12

Market Capitalization

$111.8 M

2023-04-12

Revenue

$3.8 M

FY, 2022

Neovasc Summary

Company Summary

Overview
Neovasc Inc. is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ for the treatment of refractory angina, the Tiara™ technology in development for the transcatheter treatment of mitral valve disease and a line of advanced biological tissue products that are used as key components in a variety of third-party medical products, such as vascular surgical patches and transcatheter heart valves.
Type
Public
Status
Active
Founded
2008
HQ
Richmond, CA | view all locations
Website
http://neovasc.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Fred Colen

    Fred Colen, President and Chief Executive Officer

  • Steve Rubin, Chairman

    • Bill Little

      Bill Little, Chief Operating Officer

    • Brian McPherson

    LocationsView all

    1 location detected

    • Richmond, British Columbia HQ

      Canada

      5138 13562 Maycrest Way

    Neovasc Financials

    Summary Financials

    Revenue (FY, 2022)
    $3.8M
    Gross profit (FY, 2022)
    $3.0M
    Net income (FY, 2022)
    ($41.2M)
    Cash (FY, 2022)
    $25.8M
    EBIT (FY, 2022)
    ($38.4M)
    Enterprise value
    $99.0M

    Footer menu